TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02512315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (DOC)
Description: Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP)
Description: Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation (CCRT)
Description: The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT)
Description: The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.
Study: NCT06584877

Intervention type: OTHER
Intervention: sample collection
Description: Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).

Intervention type: OTHER
Intervention: sample collection
Description: Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).

Intervention type: OTHER
Intervention: Seeking consent and assent
Description: Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
Study: NCT01203592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
Study: NCT03146442

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
Study: NCT06584877

Intervention type: OTHER
Intervention: Seeking consent and assent
Description: Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
Study: NCT02816645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT02184312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR medium dose
Study: NCT03146442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
Study: NCT02184312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine XR high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (VIRAMUNE®)
Study: NCT02637869

Intervention type: OTHER
Intervention: Alternative Payment Model
Description: Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
Study: NCT02859025

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anterior iliac crest graft
Description: Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lateral ramus cortical bone+BFPSC+NBBM
Description: ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anterior iliac crest graft+BFPSC+NBBM
Description: Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
Study: NCT03398759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: IV injection during induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV injection during induction
Study: NCT01973920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Icp
Study: NCT00738231

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
Study: NCT00627913

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Healon 5 injection
Description: Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthetic injection
Description: 3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
Study: NCT01860235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
Study: NCT00932191

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard phacoemulsification
Description: Cataract nucleus removal using standard amounts of ultrasound energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduced ultrasound phacoemulsification
Description: Cataract nucleus removal using less ultrasound energy and more mechanical energy.
Study: NCT04101409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Shared decision making with decision aids
Study: NCT03856801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Whole-body vibration training in hypoxia and normoxia condition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Whole-body vibration training in hypoxia and normoxia condition
Study: NCT01755598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine (GSK692342)
Description: 2 doses administered intramuscularly in the deltoid region of the arm.
Study: NCT03301649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Ivermectin Lotion 0.5%
Description: Topical lotion, generic formulation of the brand product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sklice® (Ivermectin) Lotion 0.5%
Description: Topical lotion, brand product.
Study: NCT01755598

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered intramuscularly in the deltoid region of the arm.
Study: NCT03219216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Film-coated tablet
Study: NCT03301649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Topical lotion, placebo. Has no active ingredient.
Study: NCT02574832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Administration
Description: The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
Study: NCT04113577

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.

Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
Study: NCT00814476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medtronic CareLink therapy management system
Description: At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular home use and Medtronic CareLink Therapy Management
Description: At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
Study: NCT02922127

Intervention type: DRUG
Group type: OTHER
Intervention: Ulipristal Acetate
Description: Daily use of Ulipristal Acetate

Intervention type: DRUG
Group type: OTHER
Intervention: Combined Oral Contraceptive Pill
Description: Daily use of Oral Contraceptive Pill
Study: NCT01007669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and Health check
Description: Strength training, aerobic capacity training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health check only
Description: Health check
Study: NCT01068145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Very low dose SCH 527123, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose SCH 527123, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose SCH 527123, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose SCH 527123, once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match SCH 527123, once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose capsule SCH 527123, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose capsule SCH 527123, once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose capsule SCH 527123, once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to match SCH 527123, once daily for 14 days
Study: NCT04552353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaway
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaway
Description: Drug: Voriconazole. Pharmacokinetic study under fasting conditions
Study: NCT04762004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal speech
Description: In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal singing
Description: In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
Study: NCT01943383

Intervention type: GENETIC
Intervention: iPSC
Description: Single blood draw for the production of induced pluripotent stem cells.
Study: NCT01757275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Na
Description: Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Mg
Description: 40 mg tablet once daily for 27 days
Study: NCT03774355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG1801
Description: Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGL1802
Description: Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
Study: NCT03955458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: FICB with EXPAREL + Bupivacaine HCL (single dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: FICB with continuous infusion of ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: FICB with EXPAREL + Bupivacaine HCL (Single dose)
Study: NCT00613171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571
Description: STI571 tablets taken orally once a day
Study: NCT00714116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: Single IV or SC dose of SBI-087
Study: NCT01220271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study: NCT00191126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV, q 21 days x 3 cycles

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Description: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery
Study: NCT03027960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10mg empagliflozin for a 2-week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10mg empagliflozin for a 2-week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 10 mg placebo for a 2-week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: 10 mg placebo for a 2-week period
Study: NCT02770482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: spinal fluid collection
Study: NCT01937871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: OTHER
Intervention: 0.2 mg Tamsulosin
Description: Administered orally
Study: NCT04500717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib plus carboplatin and pemetrexed
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study: NCT03399513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib Oral Capsule [Imbruvica]
Description: Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOEP chemotherapy
Description: Immunochemotherapy
Study: NCT04061239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Azacitidine
Description: Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
Study: NCT05175703

Intervention type: DEVICE
Group type: OTHER
Intervention: Passeo-18 Lux Paclitaxel releasing Balloon Catheter
Description: collect short term and long term clinical evaluation data of the Passeo-18 Lux Paclitaxel releasing balloon catheter, subject to patients who visit hospital from arteriosclerosis in the infrainguinal arteries in actual clinical environment.
Study: NCT01220271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered as approved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered as approved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered as approved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered as approved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally
Study: NCT03173716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Definity
Description: Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
Study: NCT01234233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duration of preoperative active warming
Description: duration of prewarming by forced air warming

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duration of preoperative active warming
Description: duration of prewarming by forced air warming

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duration of preoperative active warming
Description: duration of prewarming by forced air warming
Study: NCT03099551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group using manual toothbrush Curaprox 5460 Ultra Soft
Description: Manual toothbrush usage with Bass technique twice a day during 2 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group using sonic toothbrush Edel White
Description: Sonic toothbrush usage twice a day during 2 minutes